The complexity of the treatment of patients with chronic lymphocytic leukemia has increased
substantially over the past several years as a consequence of the advent of novel biological …

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Abstract Treatment options for chronic lymphocytic leukemia (CLL) have improved with the
introduction of the B-cell receptor inhibitors ibrutinib and idelalisib, and of the BCL2 inhibitor …

Therapy for chronic lymphocytic leukemia has improved dramatically over the past decade
with the introduction of new targeted therapies and a paradigm shift toward targeted …

Only chronic lymphocytic leukemia (CLL) patients with active or symptomatic disease or with
advanced Binet or Rai stages require therapy. Prognostic risk factor profile and comorbidity …

In recent years there has been significant progress in the treatment of chronic lymphocytic
leukemia, first due to the introduction of immunochemotherapy with monoclonal antibodies …

Recently, the use of novel targeted drugs has changed the treatment paradigms in chronic
lymphocytic leukemia (CLL). Among the several drugs used for the management of …

The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound
change. First, several new drugs have been approved (fludarabine, bendamustine and two …

Introduction: The critical role of the tissue microenvironment and B-cell receptor (BCR)
signaling in chronic lymphocytic leukemia (CLL) pathogenesis, and the clinical success of …

Chemoimmunotherapy is the established first-line treatment of patients with chronic
lymphocytic leukemia (CLL) who do not display the high-risk genetic features del (17p) …